Current status of experimental therapeutics for prostate cancer.
Hormone refractory prostate cancer (HRPC) is the progression of disease in the presence of castrate serum levels of testosterone with a median survival of approximately 1 year. A variety of strategies have been developed to improve survival for the patients with advanced prostate cancer. Despite such efforts, the effective treatment modality for those patients has not been established other than chemotherapy. New experimental therapeutics such as gene therapy, vaccine therapy and target therapy use various mechanisms to kill tumor cells selectively while sparing surrounding normal tissues. Furthermore, new approaches in the field of chemoprevention are being made. Recent data from landmark studies, in particular vaccines, have shown improvements in overall survival of HRPC patients.
Moon
Chulso
C
Department of Otolaryngology and Head and Neck Cancer Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, United States. cmoon5@jhmi.edu
Park
Jong Chul
JC
Chae
Young Kwang
YK
Yun
Jin Han
JH
Kim
Saechul
S
D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000235:genetics / Q000627:therapeutic use; D019496:Cancer Vaccines; D015316:Genetic Therapy; D005822:Genetic Vectors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000628:therapy*
D016588:Anticarcinogenic Agents; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor